Alcidion (ASX:ALC) inks A$35m UHSussex deal, front-loads A$8.5m into FY26

An upfront licence fee front-loads FY26 revenue while extension rights lift potential TCV to A$49m

Six months after being named preferred supplier, Alcidion (ASX:ALC) has formally signed its University Hospitals Sussex contract. The deal is worth approximately A$35 million over an initial seven-year term, with extension rights that could lift the total to A$49 million over ten years.

The signed contract removes the last sliver of execution risk hanging over the preferred-supplier announcement that pushed the stock up 15% earlier this year. It is now Alcidion’s largest UK contract and its third electronic patient record (EPR) win in that market.

What surprised us is the FY26 revenue recognition. Management expects to book around A$8.5 million from UHSussex this financial year, driven largely by an upfront licence fee covering the seven-year platform usage. That is a meaningful chunk of revenue landing immediately rather than being spread evenly across the contract life.

Implementation begins now, with a phase-one go-live targeted for June 2027. For investors watching Alcidion grind toward sustainable profitability, this should settle the question of whether the UK strategy is working.

Why the A$8.5m upfront recognition reshapes the FY26 print

Alcidion entered FY26 with contracted revenue of around A$43 million, already ahead of total FY25 revenue. The UHSussex licence fee now layers another A$8.5 million on top, most of it hitting the books before the platform even goes live.

There is a A$2 million third-party payment for the medications management module that will partially offset the gross contribution. Even so, the net effect on FY26 should be material, and it removes any need for management to talk down expectations into the August result.

We think the more interesting question is what this does to FY27. With the upfront fee absorbed in FY26, the residual contract value spreads across the remaining six years as recurring revenue. That is the profile institutional buyers of small-cap software actually want to see.

The modular structure is doing more work than the headline TCV suggests

The contract covers Miya Observations and Assessments (Patientrack), already live at UHSussex, plus the first UK deployment of Alcidion’s virtual care module for remote patient monitoring. The deal also leaves the door open for Miya Emergency and a Patient Administration System to be added later.

This is the playbook Alcidion has been promising for years. Land a base EPR contract, then upsell additional modules into a customer already integrated on the platform. UHSussex covers seven hospitals, one million people and 20,000 staff, so the upsell runway inside this single account is substantial.

The skeptical read is that none of those extension modules are signed yet, and the rights to extend out to ten years are just options. The A$49 million ceiling is real but it is not guaranteed revenue.

Three UK EPR contracts now make this a genuine reference business

UHSussex is Alcidion’s third EPR platform contract in the UK. For a company that spent years selling point solutions into the NHS, having three EPR deployments changes the sales conversation entirely.

NHS trusts evaluating digital transformation vendors tend to follow each other. Three reference sites, including one of the largest acute trusts in the country, is the kind of credibility that opens doors at the next tender.

The Investors Takeaway for Alcidion

Today’s signing closes the UHSussex chapter cleanly and front-loads A$8.5 million into FY26. Combined with the dual SaMD AI registration earlier this year and contracted revenue already north of A$43 million, the operational picture looks the strongest it has been since listing.

OK, so when will it become the next Pro Medicus? Well, truth be told, it may never become Pro Medicus in the sense of being a multibagger. But for some kind of re-rating, we believe investors would want to see two things over the next twelve months. First, evidence the virtual care module deployment is working, because that is the upsell template for the rest of the UK book. Second, a fourth NHS EPR contract that confirms this is a repeatable sales motion rather than three one-off wins. Investors can read our previous coverage of Alcidion’s dual AI approval and preferred supplier milestone at stocksdownunder.